Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

AbbVie: Clinical Trials & FDA Approval Profile

AbbVie (North Chicago, IL) sponsors 324 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 128 active protocols (66 recruiting now), 150 completed protocols, and 189 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)14.2%
Median Closed Enrollment vs National (145 pts)184 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for AbbVie
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)324
Active Pipeline (Recruiting Now)128 (66)
Completed vs Stopped Early150 / 46 (14.2%)
Median Closed Actual Enrollment184 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals189 (19 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With AbbVie
Hospital Research SiteLocationShared Protocols
Washington University and Siteman Cancer CenterSaint Louis, MO36
University of Chicago MedicineChicago, IL34
Ohio State University Comprehensive Cancer CenterColumbus, OH34

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by AbbVie
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06575192Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult ParticipantsPhase IIIRECRUITING
NCT07196644A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or MetastaticPhase IIRECRUITING
NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab SoravtansinPhase IIRECRUITING
NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseasePhase IIRECRUITING
NCT06890338A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly DiPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the AbbVie Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI